• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

造血干细胞移植克服准入差距的演进：NMDP 的作用。

The Evolution of Hematopoietic Stem Cell Transplantation to Overcome Access Disparities: The Role of NMDP.

机构信息

NMDP, Minneapolis, MN 55401, USA.

CIBMTR (Center for International Blood and Marrow Transplant Research), NMDP, Minneapolis, MN 55401, USA.

出版信息

Cells. 2024 May 29;13(11):933. doi: 10.3390/cells13110933.

DOI:10.3390/cells13110933
PMID:38891065
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11171651/
Abstract

NMDP recognizes that despite advances in hematopoietic stem cell transplantation (HSCT) and other cell therapies, not all patients have equitable access to treatment, and disparities in outcomes remain. This paper explores the recent work of NMDP to accelerate progress and expand access to more patients through transformative clinical research, particularly in the use of mismatched unrelated donors for HSCT.

摘要

NMDP 认识到，尽管造血干细胞移植（HSCT）和其他细胞疗法取得了进展，但并非所有患者都能平等获得治疗，治疗结果仍存在差异。本文探讨了 NMDP 最近的工作，通过变革性临床研究加速进展并扩大更多患者的治疗机会，特别是在 HSCT 中使用不匹配的无关供体方面。

相似文献

1
The Evolution of Hematopoietic Stem Cell Transplantation to Overcome Access Disparities: The Role of NMDP.造血干细胞移植克服准入差距的演进：NMDP 的作用。
Cells. 2024 May 29;13(11):933. doi: 10.3390/cells13110933.
2
Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR.无关供者和脐带血造血细胞移植的选择：来自 NMDP/CIBMTR 的指南。
Blood. 2019 Sep 19;134(12):924-934. doi: 10.1182/blood.2019001212. Epub 2019 Jul 10.
3
Outcomes in Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia.先天性巨核细胞血小板减少症造血干细胞移植的结果。
Transplant Cell Ther. 2022 Feb;28(2):101.e1-101.e6. doi: 10.1016/j.jtct.2021.10.009. Epub 2021 Oct 17.
4
The National Marrow Donor Program: improving access to hematopoietic cell transplantation.国家骨髓捐献项目：改善造血细胞移植的可及性。
Clin Transpl. 2011:55-62.
5
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic and Advanced Phase Myelofibrosis.慢性和晚期骨髓纤维化患者异基因造血干细胞移植的结果
Biol Blood Marrow Transplant. 2016 Dec;22(12):2180-2186. doi: 10.1016/j.bbmt.2016.08.029. Epub 2016 Sep 3.
6
Improving Unrelated Donor Equity: Assessing Mismatched Donor Opportunities with Real-World Data in a Minority-Predominant Cohort.提高非亲缘供者公平性：在以少数族裔为主的队列中使用真实世界数据评估不匹配供者机会。
Transplant Cell Ther. 2024 May;30(5):544.e1-544.e8. doi: 10.1016/j.jtct.2024.02.020. Epub 2024 Feb 28.
7
Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.来自HLA匹配供者和替代供者的异基因造血干细胞移植的结局：欧洲血液与骨髓移植学会登记处的回顾性分析
Lancet Haematol. 2019 Nov;6(11):e573-e584. doi: 10.1016/S2352-3026(19)30158-9. Epub 2019 Aug 30.
8
CD3TCRαβ/CD19-Depleted Mismatched Family or Unrelated Donor Salvage Stem Cell Transplantation for Graft Dysfunction in Inborn Errors of Immunity.CD3TCRαβ/CD19 耗竭的 mismatched 家族或无关供者挽救性干细胞移植治疗先天性免疫缺陷中的移植物功能障碍。
Transplant Cell Ther. 2023 Aug;29(8):513.e1-513.e9. doi: 10.1016/j.jtct.2023.05.019. Epub 2023 Jun 4.
9
Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.多中心分析表明，在 HLA 匹配的相关和无关造血干细胞移植后，次要组织相容性抗原对移植物抗宿主病和移植物抗肿瘤效应具有显著的临床影响。
Biol Blood Marrow Transplant. 2013 Aug;19(8):1244-53. doi: 10.1016/j.bbmt.2013.06.001. Epub 2013 Jun 10.
10
Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?异基因造血细胞移植受者的更佳供者是谁：年轻 HLA 错配半相合亲属，还是年长的完全 HLA 匹配的同胞或无关供者？
Biol Blood Marrow Transplant. 2019 Oct;25(10):2054-2060. doi: 10.1016/j.bbmt.2019.05.031. Epub 2019 Jun 4.

本文引用的文献

1
Existence of HLA-Mismatched Unrelated Donors Closes the Gap in Donor Availability Regardless of Recipient Ancestry.HLA 错配非亲缘供者的存在缩小了供者来源的差距，而与受者的种族无关。
Transplant Cell Ther. 2023 Nov;29(11):686.e1-686.e8. doi: 10.1016/j.jtct.2023.08.014. Epub 2023 Aug 14.
2
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.移植后环磷酰胺为基础的移植物抗宿主病预防。
N Engl J Med. 2023 Jun 22;388(25):2338-2348. doi: 10.1056/NEJMoa2215943.
3
Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research.
真实世界数据显示异基因造血细胞移植中种族和民族的趋势和结果：来自国际血液和骨髓移植研究中心的报告。
Transplant Cell Ther. 2023 Jun;29(6):346.e1-346.e10. doi: 10.1016/j.jtct.2023.03.007. Epub 2023 Mar 15.
4
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial.移植后环磷酰胺在非血缘骨髓移植受者中的 3 年结果：一项全国骨髓供者计划赞助的前瞻性临床试验的随访。
Transplant Cell Ther. 2023 Mar;29(3):208.e1-208.e6. doi: 10.1016/j.jtct.2022.12.017. Epub 2022 Dec 27.
5
The ASTCT-NMDP ACCESS Initiative: A Collaboration to Address and Sustain Equal Outcomes for All across the Hematopoietic Cell Transplantation and Cellular Therapy Ecosystem.ASTCT-NMDP ACCESS 倡议：为了在造血细胞移植和细胞治疗生态系统中实现所有参与者的平等结果而进行的合作。
Transplant Cell Ther. 2022 Dec;28(12):802-809. doi: 10.1016/j.jtct.2022.09.020. Epub 2022 Sep 30.
6
Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation.用于预防移植物抗宿主病的阿巴西普可通过消除无关供体干细胞移植中配型不相合的影响来减少种族差异。
Blood Adv. 2022 Feb 8;6(3):746-749. doi: 10.1182/bloodadvances.2021005208.
7
Optimal Donor Selection for Hematopoietic Cell Transplantation Using Bayesian Machine Learning.基于贝叶斯机器学习的造血干细胞移植最优供者选择。
JCO Clin Cancer Inform. 2021 May;5:494-507. doi: 10.1200/CCI.20.00185.
8
National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.国家骨髓捐赠者计划-赞助的 HLA 错配无关供者骨髓移植使用移植后环磷酰胺的多中心 II 期试验。
J Clin Oncol. 2021 Jun 20;39(18):1971-1982. doi: 10.1200/JCO.20.03502. Epub 2021 Apr 27.
9
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.阿巴西普阻断共刺激用于预防急性移植物抗宿主病的 II 期临床试验。
J Clin Oncol. 2021 Jun 10;39(17):1865-1877. doi: 10.1200/JCO.20.01086. Epub 2021 Jan 15.
10
HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.美国注册中心造血干细胞移植供者 HLA 配型概率。
N Engl J Med. 2014 Jul 24;371(4):339-48. doi: 10.1056/NEJMsa1311707.